Combined modality therapy for small cell lung cancer patient with limited stage disease / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 701-703, 2007.
Article
in Chinese
| WPRIM
| ID: wpr-298514
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the efficacy of combined modality therapy for small cell lung cancer (SCLC) patient with limited stage disease (LD).</p><p><b>METHODS</b>The data of 122 SCLC patients with limited stage disease treated by surgery combined with chemotherapy and radiotherapy were analysed retrospectively.</p><p><b>RESULTS</b>The median survival time (MST) of the 122 patients was 38 months, the 1-, 3-, 5-year survival rate was 83.6%, 50.0% and 38.0%, respectively. If stratified the patients by TNM stage, the MST of stage I was not reached yet, it was 52 months for stage II and 22 months for stage III (P = 0.001); the 5-year survival rate was 57.1%, 43.1% and 28.3%, respectively. For stage III, the MST and 5-year survival rate was 40 months and 45.3% for the patients who received postoperative chemoradiotherapy, and only 20 months and 26.1% for those who were treated with postoperative chemotherapy alone (P = 0.071).</p><p><b>CONCLUSION</b>Combined modality therapy can improve the survival of small cell lung cancer patient with limited stage disease, and TNM stage is still a significant prognostic factor.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
Pneumonectomy
/
Therapeutics
/
Antineoplastic Combined Chemotherapy Protocols
/
Survival Rate
/
Retrospective Studies
/
Follow-Up Studies
/
Chemotherapy, Adjuvant
/
Radiotherapy, Adjuvant
/
Therapeutic Uses
Type of study:
Observational study
/
Prognostic study
/
Risk factors
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
Language:
Chinese
Journal:
Chinese Journal of Oncology
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS